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ABSTRACT 
 S-adenosylmethionine synthesis is a key process for cell function, and needs to 
be regulated at multiple levels. In recent years, advances in the knowledge of 
methionine adenosyltransferases have been significant. The discovery of nuclear 
localization of these enzymes suggests their transport to provide the methyl donor, S-
adenosylmethionine, for DNA and histone methyltransferases in epigenetic 
modifications, opening new regulatory possibilities. Previous hypotheses considered 
only the cytoplasmic regulation of these enzymes, hence the need of an update to 
integrate recent findings. Here, we focus mainly on the liver and redox mechanisms, 
and their putative effects on localization and interactions of methionine 
adenosyltransferases.  
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Highlights: 
- Redox stress differentially regulates methionine adenosyltransferases 
- Redox stress may regulate subcellular localization of methionine adenosyltransferases 
- S-adenosylmethionine homeostasis is regulated by redox stress 
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1. INTRODUCTION 
 Cells use methylation reactions to synthesize a large variety of compounds, 
including neurotransmitters and phospholipids, but also to regulate important functions 
such as gene expression [1-3]. For this purpose, a methyl donor is needed, a role 
performed mainly by S-adenosylmethionine (AdoMet). This metabolite is synthesized 
from methionine and ATP by methionine adenosyltransferases (MATs), which also 
hydrolyze the triphosphate chain of the nucleotide to yield pyrophosphate and inorganic 
phosphate (Fig. 1)[4]. Mammalian genomes contain three MAT genes that code for two 
catalytic subunits, α1 (MAT1A) and α2 (MAT2A), and a regulatory β-subunit (MAT2B). 
These subunits associate into three isoenzymes that are homo- (MAT I and III) and 
hetero-oligomers (MAT II)[2,5]. MAT I and MAT III are a tetramer and a dimer of α1 
subunits, respectively, whereas MAT II was recently postulated to be a hetero-trimer of 
α2 and β subunits in a 2:1 ratio (Fig. 1) [6]. These isoenzymes show different affinities 
for methionine (S0.5Met), which are low for MAT III (1 mM), intermediate for MAT I 
(100 µM) and high for MAT II (3.3-16 µM). Their Vmax follow the opposite trend 
compared to the S0.5Met, hence low AdoMet levels correlate with MAT II expression and 
high levels of the methyl donor with MAT I/III expression [2,3,5] (Fig. 1). Isoenzyme 
expression is tissue-dependent, that of MAT I/III being maximal in the liver [7,8] 
whereas MAT II is the prevalent isoenzyme in extrahepatic tissues [2]. Based on these 
kinetic and expression data, the capacity to synthesize AdoMet is higher in the liver 
than in other tissues and its levels are the highest followed closely by those found in 
kidney [8]. In contrast, the hepatic methylation index (AdoMet/S-
adenosylhomocysteine ratio) is lower than in other tissues, a fact related to the number 
and importance of hepatic transmethylation reactions, and the resulting S-
adenosylhomocysteine production [1,8]. 
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 Classically, MATs were considered cytosolic proteins and MAT I/III the hepatic 
isoenzymes; therefore, the previous hypothesis on their regulation was focused on 
cytosolic MAT I/III activity and association state [9], suggesting the need to explore 
post-translational modifications affecting these isoenzymes. This led to detailed studies 
on the redox and phosphorylation mechanisms acting on MAT I/III, which assumed that 
AdoMet synthesized in the cytosol was transported to compartments such as the nucleus 
for its use in methylation reactions (e.g. histone and DNA methylation). However, in 
2009 our group demonstrated the nuclear localization of MAT I [7], a report that was 
shortly followed by the description of MAT II and splicing variants of the β-subunit in 
the nucleus [10,11]. These articles related nuclear localization of MATs to enhanced 
histone methylation, therefore suggesting that MATs are recruited to these locations 
where AdoMet synthesis is needed, as pointed out in an editorial article accompanying 
Katoh’s paper [12]. These data, together with the accumulated knowledge on structure, 
post-translational modifications, and nuclear association states, prompted us to update 
and expand the previous regulatory model, incorporating also data concerning MAT II. 
 
2. STRUCTURAL DATA ON METHIONINE ADENOSYLTRANSFERASES 
 Crystal structures of several MAT homo-oligomers in free active site 
conformations or complexed with substrates, products, or their analogues are now 
available [5,13,14]. These structures also included Mg2+ and K+ ions and NADP+. The 
three-domain organization of α1-monomers is preserved in α2-subunits and, given the 
high level of sequence conservation among catalytic subunits [15], this organization is 
expected to be a common feature throughout the MAT family. A large hydrophobic 
surface constitutes the monomer-monomer interface, where the two dimer active sites 
are opposed to one another. Both monomers contribute residues to the active sites, and 
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hence monomers are unable to synthesize AdoMet. Access to the active site is 
controlled by a flexible loop that contains a cysteine residue in α1 [5,13]. The small 
interface between dimers in the tetramer involves the central domain of the α-subunits, 
fewer interactions contributing to dimer association in mammalian tetramers than in 
their E. coli counterpart [16].  
 The regulatory β-subunit shows no structural relationship with α-subunits and 
has been classified as a member of the oxidoreductase PFAM 04321 family. As such, 
the β-subunit contains a FAD+/NADP+ Rossman fold, where NADP+ has been 
crystallized. Binding of the cofactor induces ordering into three regions (A-C) of the 
subunit, two of them (A and B) directly involved in NADP+ binding [6]. The MAT II 
hetero-oligomer interface is proposed to involve regions A and C of the β-subunit, 
together with the central domain of α2-subunits [6].  
 
3. METHIONINE ADENOSYLTRANSFERASES IN PATHOLOGY 
 Most studies on the pathophysiological role of MAT isoenzymes have been 
carried out in liver (recently reviewed in [17]), where ∼50% of the ingested methionine 
is metabolized [18]. However, alterations in expression of MAT isoenzymes and 
AdoMet levels have been reported in a variety of pathologies that include hepatocellular 
carcinoma (HCC), diabetes, and Alzheimer’s or Wilson’s disease [2,3,19]. HCC studies 
showed changes in promoter methylation of MAT1A (hypermethylated) and MAT2A 
(hypomethylated), leading to an expression switch towards reduced MAT1A and 
increased MAT2A mRNA levels, that is followed by enhanced MAT2B expression 
[17,20]. This expression switch correlates with a reduction in hepatic AdoMet levels, as 
expected from the exchange from high Vmax isoenzymes to low Vmax MAT II 
[2,3,17,21](Fig. 1). The link between HCC and AdoMet levels has been confirmed 
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using two knockout mouse models that exhibited either low (MAT1A KO) or high 
(glycine N-methyltransferase, GNMT KO) hepatic AdoMet concentrations and that 
spontaneously developed HCC [22,23]. This relationship has been strengthened by 
knocking down microRNAs (miR-664, miR-485-3p, miR-495) that are highly 
expressed in HCC and reduce MAT1A expression [24]. A large amount of work has 
been devoted to elucidating the signaling cascades relating changes in AdoMet 
synthesis and disease (reviewed in [17]). Among them are those involving NFκB and 
AP-1, for which MAT2A and MAT2B promoters include binding sites and that also 
induce iNOS expression, thus enhancing nitric oxide (NO) production leading to MAT 
I/III inhibition (see below).  
 In contrast, most human MAT1A mutations are asymptomatic, and only in a few 
individuals demyelination has been reported [25]. These neurological symptoms were 
described for patients with alterations in the C-terminal end of the α1-subunit, but only 
in one case was exogenous AdoMet used to obtain an improvement in myelination 
[25,26]. Importantly, a mutant form with an alteration at the C-terminal end, analogous 
to those causing human demyelination, showed nuclear accumulation in living cells [7]. 
The process by which demyelination occurs is unknown, although an anomalous α1/α2 
oligomerization was postulated to reduce AdoMet synthesis [27]. The availability of the 
structures for MAT subunits, data showing expression of MAT1A in extrahepatic 
tissues, and the demonstration that MATα1 localizes mainly to the nucleus in most cell 
types except hepatocytes, allowed reexamination of this hetero-oligomerization 
hypothesis in 2011 [28].  
 
4. METHIONINE ADENOSYLTRANSFERASES AND REDOX STRESS 
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 Several disease models, including treatments with carbon tetrachloride [29] or 
lipopolysaccharide [30], buthionine sulfoximine intoxication [31], and Long Evans 
Cinnamon rats (LEC; Wilson’s disease model)[19], have shown a relationship between 
redox stress and MAT function. In these models reductions in glutathione synthesis, 
alterations in expression of MAT genes, lower levels of MATα1 and/or inhibition of 
MAT I/III activity were observed. Results derived from these studies, together with in 
vitro experiments carried out in parallel, demonstrated MAT I/III inhibition by GSSG 
and modulation of this activity by the GSH/GSSG ratio [32,33]. Redox stress also 
altered the association state of MAT I/III, leading to either the accumulation of inactive 
dimers or even monomers [32,34]. Moreover, C121, the cysteine located at the active 
site loop of MAT I/III, was modified by NO and hydroxyl radicals in some of these in 
vivo models, leading to enzyme inactivation [35-37]. Therefore C121 nitrosylation was 
proposed to force the loop into a position that blocks substrate admission into the 
catalytic site, thus precluding AdoMet synthesis.  
 The key role of cysteine residues in activity and oligomerization of MAT I/III 
was also demonstrated using chemical modification or mutagenesis [38-40]. The C69S 
mutant accumulated as α1-dimers and elimination of cysteines between positions 35-
105 altered MAT I/III ratios [40]. However, none of these individual mutations fully 
inactivates MAT I/III [16,40]. Additionally, in vitro production of the C35-C61 
intrasubunit disulfide bond blocked dimer-tetramer interconversion, without affecting 
activity [16]. This disulfide in the central domain was a normal feature of the purified 
hepatic α1-oligomers [41], and the conformational changes it induced were observed as 
subtle changes in SDS-PAGE mobility of MATα1 upon thiopropyl Sepharose 
purification [32]. 
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 Hepatic copper accumulation in LEC rats induces redox stress, the MAT1A to 
MAT2A expression switch, inhibition of MAT I/III activity, and decreased AdoMet 
levels [19]. In contrast, MAT2B expression is almost suppressed. The consequence is 
that MAT II oligomers in these livers must be mainly composed by α2-subunits with 
higher S0.5Met than MAT II hetero-oligomers [2]. Moreover, copper altered folding of α1 
and α2-subunits in the test tube, suggesting a potential folding problem in vivo. The 
lack of cysteines equivalent to C121 and C61 in the MATα2 sequence precludes 
inhibition by NO or intrasubunit disulfide production [5,15], and no reports have shown 
whether MATα2 activity can be modulated by GSH/GSSG ratios. Therefore, a redox 
regulatory mechanism similar to that described for MAT I/III seemed unlikely for MAT 
II. Our recent report demonstrating increased affinity of NADP+-bound β-subunit for 
α2-dimers [6], suggests that high levels of this cofactor (e.g., during drug 
detoxification) would favor production of MAT II. These data open the possibility that 
redox regulation is exerted on different subunits and with opposite results for AdoMet 
production in each type of MAT isoenzyme.  
 
5. PROPOSED HYPOTHESIS 
 All the data summarized in the previous sections suggest a redox regulatory 
mechanism controlling mammalian MAT isoenzymes in a concerted way (Fig. 2). This 
redox mechanism directs AdoMet production at several levels including MAT 
expression, activity, oligomerization, and potentially subcellular localization. Only 
some of the models studied to date showed MAT expression changes induced by 
oxidative stress (reviewed in [2,17]). Lack of consensus sequences for metal (MREs) or 
antioxidant (AREs) response elements in the corresponding promoters precludes direct 
effects through binding of transcription factors to such elements, as previously 
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discussed [19]. Other options include promoter binding of redox stress-regulated 
transcription factors (e.g., NFκB in MAT2B and MAT2A)[2,42], changes in promoter 
methylation status directly or indirectly involving redox regulation of demethylases or 
methyltransferases [43,44], or changes in other epigenetic modifications controlled by 
redox stress (e.g., sirtuin binding of NAD+) (Fig. 2A). Additionally, MAT1A and 
MAT2A mRNAs can be regulated by 3’-UTR binding of AUF1 or meHuR/HuR, 
respectively [45], an AdoMet-dependent process that could be modulated by redox 
mechanisms. 
 Under diverse redox conditions distinct subunit associations can be produced 
that may differ among subcellular compartments. Thus, fully reduced recombinant 
subunits appear in a tetramer/dimer concentration-dependent equilibrium [46,47] (Fig. 
2B; step 1). However, in liver cytosol MATα1 homo-oligomers are stable, a fact 
ascribed to the presence of the C35-C61 intrasubunit disulfide (step 2)[16,41,46]. Under 
redox stress the GSH/GSSG ratio is reduced (<50) and different oxidation degrees could 
be produced favoring dissociation into dimers (step 4; observed in cirrhotic livers) or 
even into inactive α1-monomers (step 5)[32]. Moreover, in vivo C121 nitrosylation can 
be the initial oxidation event, followed by the GSSG effects (steps 4 and 5). Altogether 
these changes result in reduction of cytosolic MAT I/III activity during redox stress, and 
hence of AdoMet levels available for methylation.  
 Confocal microscopy demonstrated the presence of nuclear MATα1-EGFP in 
living cells [7], but the mechanisms that govern its subcellular localization are 
unknown. Among the possibilities, protein-protein interactions may induce direct or 
indirect binding of the homo-oligomer to importins or exportins (step 6), a step that 
might be favored by the presence of post-translational modifications on MATα1. Redox 
stress is a putative mechanism controlling subcellular localization, but there is no 
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available information concerning the redox state of the nuclear MATα1 forms. 
Therefore, our proposal includes transport of fully reduced or partially oxidized 
MATα1 oligomers through the nuclear pore (step 6), and oxidation/reduction of these 
species if nuclear GSH/GSSG ratios change (step 7). Given that MAT activity is 
detected in nuclear fractions [7], nuclear MAT I species must be active to synthesize 
AdoMet, and nuclear monomers may arise from tetramer dissociation (step 8). Again, 
the reduced/oxidized character of these monomers is unknown, but they may associate 
into MAT I when higher nuclear levels of AdoMet are needed for epigenetic 
remodeling. Truncation of the C-terminal end of MATα1 induced nuclear accumulation 
[7]; hence, modifications in residues in this area of the molecule, such as T342 
phosphorylation [48] or others that have been detected by proteomic approaches 
(PhosphoSite Plus), may play a role in subcellular localization.  
 Several cell culture experiments and MATα2 and β purification from 
mammalian tissues demonstrated the existence of MAT II hetero-oligomers (Fig. 
2C)[6]. In bacterial cytosol, a reduced environment, both recombinant subunits appear 
in equilibrium-dependent associations, dimers and tetramers for α2 (step 1) and 
monomers and dimers for β-subunits (step 9)[6]. In vitro, β-monomers can bind NADP+ 
(step 10), but both free- and NADP+-bound subunits associate into stable MAT II 
hetero-trimers (steps 11 and 12). NO production, drug detoxification and GSSG 
reduction enhance NADP+ levels (Fig. 1). Under these conditions the affinity of 
NADP+-β for α2-dimers is increased (steps 10 and 12), and MAT II association (with 
the lower Vmax) is favored leading to reduced AdoMet levels in the cytosol. However, 
not all the splicing forms of the β-subunit can bind NADP+, thus providing selectivity to 
this regulation mechanism [6,42].  
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 Indirect immunofluorescence detected nuclear MAT II, where α2-subunits 
interact with the MafK transcription factor, acting as corepressors [10]. The 
mechanisms of nucleocytoplasmic transport of MAT II remain also unknown, although 
again protein-protein interactions or post-translational modifications might be involved 
(step 13). These putative modifications may result from oxidative stress, a point that 
deserves investigation. Moreover, NADP+ binding may favor one or another subcellular 
localization (step 13), the cofactor being lost once the adequate compartment is reached 
(step 14). Additional modifications in α2 and β-subunits that may have a role in 
localization include those identified by mass spectrometry (PhosphoSite Plus) 
[49,50,51]. Despite the similarity among C-terminal ends of MATα1 and MATα2, the 
small differences detected may allow differential regulation of their subcellular 
localization [7].  
 All these association changes render species differing in their Vmax, and hence in 
AdoMet production. When liver function is normal the high Vmax MAT isoenzymes are 
prevalent, synthesizing enough AdoMet to meet cell requirements. However, when 
hepatic function is challenged, the defense or drug detoxification mechanisms induce 
production of NO, GSSG and/or increased NADP+ levels (Fig. 1). All these metabolic 
changes led to inhibition of the normal hepatic isoenzymes (MAT I/III) and increased 
levels of MAT II, the net result being a reduction of the AdoMet levels available for 
methylation reactions (e.g., DNA hypomethylation). These concerted actions guarantee 
AdoMet synthesis in the cytosol under a minimum supply of methionine, but whether 
the same effects can be extrapolated to nuclear behavior should be explored. 
  In summary, redox stress data suggest a fundamental role for this mechanism in 
AdoMet homeostasis. Negative effects on MAT I/III would be exerted at different 
levels from expression to activity of the α1-subunit, whereas compensatory/positive 
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effects on MAT II would occur through the regulatory β-subunit. The putative role of 
these mechanisms in governing subcellular localization of MATs and the relationship 
between changes in localization and pathology remain unexplored.  
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FIGURE LEGENDS 
Figure 1. Metabolic links between redox stress and AdoMet synthesis.  A schematic 
representation of the reactions linking AdoMet and glutathione synthesis (black dashed 
lines) is shown, together with actions of glutathione, nitric oxide (NO) and NADP+ 
(green circles) levels on methionine adenosyltranferases. MATα1 subunits 
(aquamarine) appear as homotetramers (MAT I) and homodimers (MAT III) that are 
inhibited by GSSG or NO (red dashed lines). MATα2 subunits (blue) appear as 
homodimers or heterotrimers (MAT II) with the β-subunit (red). Reactions involved in 
NADP+ synthesis and the increased β/α2-dimer affinity produced by cofactor binding 
(green dashed lines) are shown. 
 
Figure 2. Scheme of redox regulation. Experimental changes affecting MATs are 
shown (thick arrows), together with putative additional points of redox-regulation 
(dotted arrows). Effects on transcription (A), including promoter methylation and 
putative binding of redox-regulated transcription factors, are depicted together with 
factors affecting mRNA stability. Thick lines denote results concerning MAT I/III (B) 
or MAT II (C) proteins in animal models and living cells (green) or in vitro (black), and 
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putative reactions appear as dotted lines. Fully reduced MATα1 (aquamarine) and 
MATα2 (blue), appear in a concentration-dependent equilibrium between tetramers and 
dimers (1). Partially oxidized MATα1 (orange), containing the C35-C61 intrasubunit 
disulfide (C-C), associate into stable oligomers (2-3). NO and GSSG inhibition (4) and 
full oxidation and dissociation (5) are also depicted. Putative redox-regulated steps of 
MAT transport through the nuclear pore complex (NPC) and nuclear function are 
indicated, considering also putative interactions with unidentified X-proteins (6-8). Free 
β-subunits (red) appear as monomers and dimers (9) to which NADP+ (green circles) 
binds (10), and which can associate with α2-dimers into heterotrimers (11-12). Putative 
redox-regulated steps for MAT II transport and function in the nucleus, including 
association with MafK transcription factor, are indicated (13-14). 
 




